胰腺原位癌与T1a/T1b胰腺导管腺癌的临床和影像学差异
回顾性分析37例患者(23例胰腺原位癌,14例T1a/T1b胰腺导管腺癌),评估DWI受限扩散和PET-CT的FDG摄取在鉴别诊断中的价值。PET-CT FDG摄取在T1a/T1b胰腺导管腺癌组为42.9%,显著高于胰腺原位癌组的4.3%(p=0.007),是多变量分析中唯一的独立预测因子(OR 13.1,95%CI 1.29-134.0,p=0.030),特异度95.7%,总体诊断准确率75.7%。作者认为PET-CT FDG摄取可能有助于鉴别,但需更大样本前瞻性研究进一步验证。
要点
- PET-CT显示FDG摄取在T1a/T1b胰腺导管腺癌组为42.9%(6/14),胰腺原位癌组仅4.3%(1/23),差异有统计学意义(p=0.007)。
- PET-CT FDG摄取检测T1a/T1b胰腺导管腺癌的特异度达95.7%,总体诊断准确率75.7%。
- DWI受限扩散在T1a/T1b胰腺导管腺癌组为50.0%,胰腺原位癌组为17.4%,但差异未达统计学显著(p=0.063)。
核心结论
- PET-CT的FDG摄取可能有助于鉴别T1a/T1b胰腺导管腺癌与胰腺原位癌;结合这些表现的多模态影像方法可能支持更个体化的治疗规划,但需更大样本前瞻性研究进一步验证。
研究设计与样本
- 回顾性分析37例术前接受CT、MRI、超声内镜和18F-FDG PET-CT检查的患者,其中胰腺原位癌23例、T1a/T1b胰腺导管腺癌14例,比较两组影像表现并行Logistic回归分析。
关键影像表现/征象
- T1a/T1b胰腺导管腺癌组PET-CT显示FDG摄取者6例(42.9%),胰腺原位癌组仅1例(4.3%)。
- T1a/T1b胰腺导管腺癌组DWI显示受限扩散者占50.0%,胰腺原位癌组占17.4%。
- 原文比较的影像表现还包括主胰管周围低回声区。
诊断标准与关键数值
- PET-CT FDG摄取检测T1a/T1b胰腺导管腺癌的敏感度为42.9%(6/14)、特异度为95.7%、总体诊断准确率为75.7%。
- DWI受限扩散检测T1a/T1b胰腺导管腺癌的敏感度为50.0%、特异度为82.6%。
- 多变量分析中PET-CT FDG摄取是T1a/T1b胰腺导管腺癌的独立预测因子(OR 13.1,95%CI 1.29-134.0,p=0.030)。
临床应用与阅片要点
- 作者认为PET-CT的FDG摄取可能有助于鉴别T1a/T1b胰腺导管腺癌与胰腺原位癌。
- 作者认为结合FDG摄取等表现的多模态影像方法可能支持更个体化的治疗规划。
局限性
- 原文结论指出需更大样本前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVES: Accurate differentiation between pancreatic carcinoma in situ (CIS) and small invasive pancreatic ductal adenocarcinoma (PDAC) is critical for optimizing patient management. This study aimed to assess the diagnostic performance of restricted diffusion on DWI and FDG uptake on PET-CT in distinguishing T1a/T1b PDAC from CIS.
METHODS: We retrospectively analyzed 37 patients (23 with CIS and 14 with T1a/T1b PDAC) who underwent preoperative CT, MRI, endoscopic ultrasonography (EUS), and 18F-fluorodeoxyglucose (FDG) PET-CT. Imaging findings, including hypoechoic area around the main pancreatic duct, restricted diffusion on diffusion-weighted MRI (DWI-MRI), and FDG uptake on PET-CT, were compared between the groups. Logistic regression analyses were performed to identify predictors of T1a/T1b PDAC.
RESULTS: Among the T1a/T1b PDAC group, FDG uptake was observed in 6 (42.9%), contrasting sharply with only 1 of 23 CIS patients (4.3%) (p = 0.007). Restricted diffusion on DWI was more frequent in T1a/T1b PDAC (50.0%) than in CIS (17.4%), but did not reach statistical significance (p = 0.063). FDG uptake on PET-CT demonstrated the highest specificity (95.7%) for detecting T1a/T1b PDAC, resulting in an overall diagnostic accuracy of 75.7%. DWI offered a specificity of 82.6% but only moderate sensitivity (50.0%). In multivariable analysis, FDG uptake on PET-CT emerged as the sole independent predictor of T1a/T1b PDAC (odds ratio, 13.1; 95% confidence interval, 1.29-134.0; p = 0.030).
CONCLUSIONS: FDG uptake on PET-CT might be helpful in differentiating T1a/T1b PDAC from CIS. A multimodal imaging approach incorporating these findings may support more individualized treatment planning; however, further validation in larger prospective studies is warranted.
引用
- Satoh T, Kawaguchi S, Nakatani E, et al. Clinical and imaging differences between pancreatic carcinoma in situ and T1a/T1b pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2026. PMID: 41838072. doi:10.1007/s00261-026-05453-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。